MannKind Corp executive RSUs vest, 93,790 shares delivered
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MannKind Corp Chief People & Workpl Officer Stuart A. Tross had a previously granted performance restricted stock unit award vest on July 15, 2026, delivering 93,790 shares of common stock. To cover taxes, a total of 65,808 shares were withheld at $4.09 per share, and his direct holdings include shares acquired through the Employee Stock Purchase Plan.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance Restricted Stock Unit F4, F1 | 93,790 | $0.00 | $0.00 |
| Exercise | Common Stock, $0.01 Par Value F1, F2 | 93,790 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock, $0.01 Par Value F3 | 33,652 | $4.09 | $138K |
| Exercise Price or Tax Liability | Common Stock, $0.01 Par Value F3 | 8,253 | $4.09 | $34K |
| Exercise Price or Tax Liability | Common Stock, $0.01 Par Value F3 | 11,572 | $4.09 | $47K |
| Exercise Price or Tax Liability | Common Stock, $0.01 Par Value F3 | 12,331 | $4.09 | $50K |
Footnotes (4)
- F1. A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.
- F2. Includes 4,038 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.
- F3. Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
- F4. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
Key Figures
Key Terms
Performance Restricted Stock Unit financial
Russell 3000 Pharmaceutical & Biotechnology Index financial
Employee Stock Purchase Plan financial
Rule 16b-3 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What RSU vesting did MannKind Corp (MNKD) report for Stuart A. Tross?
What performance goals triggered RSU vesting for MNKD's Chief People & Workpl Officer?
AI-generated analysis. How Rhea-AI works. Not financial advice.